-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Regeneron Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2010 to 2023.
- Regeneron Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $196M, a 71% increase year-over-year.
- Regeneron Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $266M, a 44.3% decline year-over-year.
- Regeneron Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was $246M, a 52.8% decline from 2022.
- Regeneron Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was $520M, a 58.4% decline from 2021.
- Regeneron Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2021 was $1.25B, a 321% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)